M
Miguel Morales
Researcher at Tel Aviv Sourasky Medical Center
Publications - 3
Citations - 667
Miguel Morales is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Vaccination & Immunoglobulin M. The author has an hindex of 3, co-authored 3 publications receiving 188 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Anat Amit Aharon,Gabi Shefer,Shai Levi,Yotam Bronstein,Miguel Morales,Tomer Ziv,Yamit Shorer Arbel,Lydia Scarfò,Erel Joffe,Chava Perry,Paolo Ghia +12 more
TL;DR: In this article, the authors evaluated humoral immune responses to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects.
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Chava Perry,Chava Perry,Efrat Luttwak,Efrat Luttwak,R. Balaban,Gabi Shefer,Miguel Morales,Anat Amit Aharon,Anat Amit Aharon,Y. Tabib,Yossi Cohen,Yossi Cohen,Noam Benyamini,Noam Benyamini,Ofrat Beyar-Katz,Ofrat Beyar-Katz,M. Neaman,M. Neaman,R. Vitkon,R. Vitkon,N. Keren-Khadmy,Maya Levin,Yair Herishanu,Yair Herishanu,Irit Avivi,Irit Avivi +25 more
TL;DR: In this paper, the humoral immune response to BNT162b2 mRNA COVID-19 vaccine was evaluated in patients with B-NHL who received two vaccine doses 21 days apart and compared with the response in healthy controls.
Journal ArticleDOI
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Irit Avivi,Irit Avivi,Roi Balaban,Tamir Shragai,Tamir Shragai,Gabi Sheffer,Miguel Morales,Anat Aharon,Noa Lowenton-Spier,Svetlana Trestman,Chava Perry,Chava Perry,Noam Benyamini,Noam Benyamini,Moshe Mittelman,Moshe Mittelman,Yaara Tabib,Yaara Tabib,Tali Bar Lev,Tali Bar Lev,Mor Zavaro,Mor Zavaro,Yair Herishanu,Yair Herishanu,Efrat Luttwak,Efrat Luttwak,Yael C Cohen,Yael C Cohen +27 more
TL;DR: In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type, and older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.